Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Kriya Therapeutics raises $313.3 funding
(Image credit: ©Hand Robot/AdobeStock) Kriya Therapeutics reported in an SEC filing it has raised $313.3 million in a recent funding round.1 The filing does not detail fund specificity or funding sources but rather only states two investors participated in the…
2-day ‘Eye-Conic’ conference kicks off in Chandigarh today – The Times of India
2-day ‘Eye-Conic’ conference kicks off in Chandigarh today The Times of India Source: Author: | Date: 2025-08-22 18:39:00 Source: Author: | Date: 2025-08-22 18:39:00
European Commission approves aflibercept biosimilar Mynzepli
AVT06, now approved for marketing in the EU as Mynzepli, is also under regulatory review in the United States and Japan. Image credit: ©artjazz – stock.adobe.com Advanz Pharma and Alvotech announced that the European Commission (EC) has approved marketing authorization for…
Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
(Image Credit: AdobeStock/Naypong Studio) Nicox has announced that the phase 3 Denali trial of NCX 470 0.1% met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline in open-angle glaucoma or ocular hypertension patients compared to the…
FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025
(Image Credit: AdobeStock/Ascannio The US Food and Drug Administration (FDA) has extended the target action dates for Regeneron Pharmaceuticals’ 2 EYLEA HD (aflibercept) Injection 8 mg regulatory submissions to the fourth quarter of 2025. The 2 regulatory submissions include a Chemistry, Manufacturing,…
VivaVision Biotech appoints Quan Dong Nguyen to its scientific advisory board
(Image credit: AdobeStock) VivaVision Biotech Co., Ltd., appointed Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, to its scientific advisory board. Nguyen is a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. He is also…
The emerging era of presbyopia-correcting eye drops: What’s next?
(Image Credit: AdobeStock/taffpixture) Since 2021, only 1 prescription eye drop for the correction of presbyopia, pilocarpine HCI ophthalmic solution 1.25% (Vuity; AbbVie), has been available, with additional options expected soon. In early 2025, a second eye drop, pilocarpine HCI ophthalmic…
AEVR’s executive director on #SeeWhatMatters and safeguarding the National Eye Institute
#SeeWhatMatters is a national advocacy campaign to raise awareness about the importance of federally funded vision research and to protect the independence of the National Eye Institute amid proposed structural changes to the NIH. (Image courtesy of #SeeWhatMatters) The Alliance…
UK MHRA approves phase 2a study for ANXV for diabetic retinopathy
(Image credit: AdobeStock/Janis Smits) UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the start of a clinical Proof of Concept phase 2a study with the drug candidate ANXV in the eye disease diabetic retinopathy (DR). Patients with newly…
FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
(Image Credit: AdobeStock/Corona Borealis) The US Food and Drug Administration (FDA) has accepted Opus Genetics’ Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal disease (IRD). Best disease, or vitelliform macular…